During his six-year tenure as Lion Biosciences’ CEO, Friedrich von Bohlen played a leading role in shaping the commercial bioinformatics landscape. Embodying the heady promise of bioinformatics in the late ‘90s, von Bohlen not only helped build a company around a suite of software tools from the European Molecular Biol-ogy Laboratory, but took the company public with a €208 million IPO in 2000, and then established a global presence through the acquisition of the US-based NetGenics in 2002.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.